Myriad’s myPath® Melanoma Test Receives Medicare Coverage
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Needham & Company Reiterates Strong Buy Rating on Myriad Genetics (MYGN) as Final LCD Issued for myPath Melanoma
March 14, 2019 10:46 AM EDTNeedham & Company analyst Stephen Unger reiterated a Strong Buy rating and $41.00 price target on Myriad Genetics (NASDAQ: MYGN) after the company announced the issuance of a final local coverage determination (LCD) for myPath Melanoma under Medicare's MolDx Program.
"This 23-gene test is... More
